A network meta-analysis comparing CAPLYTA (lumateperone) with other FDA-approved atypical antipsychotics for adjunctive treatment of major depressive disorder (MDD) found CAPLYTA superior in efficacy across four key measures and showed no significant weight gain. Presented at the 2026 NEI Spring Congress, the analysis used data from 10 clinical trials and highlighted CAPLYTA's favorable safety profile, including lower risk of akathisia and weight gain compared to other treatments. These findings offer valuable indirect comparative insights to guide treatment decisions in the absence of direct head-to-head trials, supporting CAPLYTA as an effective adjunctive option for adults with MDD who do not respond adequately to antidepressants alone.
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable...
